data were evaluated via descriptive statistics and univariate and multivariable analyses. greater-than-normal stool frequency [1, 2] . In the United States (US), the estimated prevalence of UC is 263 per 100,000 adults, and epidemiologic data suggest that the disease has become increasingly prevalent during the past decade [3] . Although slightly more than half of patients with UC have high initial disease activity followed by remission or mild disease severity, [40% of patients may have chronic continuous or intermittent symptoms of high disease activity [4] . Progression of UC may include proximal extension of the disease, colonic dysmotility, anorectal dysfunction, and an increased risk of colorectal cancer [5, 6] . The disease may adversely affect patients' daily activities and quality of life (QoL), and patients with UC have higher rates of sick leave and disability than do individuals in the general population [2, 7] .
A variety of misperceptions about UC may influence management strategies and limit opportunities for improving patient outcomes; for example, UC is commonly regarded as more benign than Crohn's disease (CD) [1] . However, despite continuing advances in the treatment of UC, approximately half of patients do not achieve sustained clinical remission [1] , and approximately 15% of patients undergo a colectomy within 20 years after UC diagnosis [8] . Although colectomy is widely seen as a definitive treatment option for UC, the procedure often leads to complications, such as acute or chronic pouchitis or the risk of infertility [1, 9] biologics/anti-tumor necrosis factor agents) in achieving each treatment goal using a scale of 1 (very poor) to 5 (very well).
Participants rated the frequency with which they used each medication class (1, never; 5, always) as induction and maintenance therapies for patients with mild, moderate, and severe UC. In addition, for each medication class, respondents indicated the number of weeks that patients with mild, moderate, and severe UC remained on the treatment before it was deemed successful or not. To assess drivers for the initiation of biologic therapy, respondents were asked to select up to five statements (from a list of 17) that might prompt them to prescribe biologic therapy. Finally, participants were asked if they experienced barriers to the use of biologic therapies, and those who answered yes were asked to select all that applied from a list of 12 potential barriers.
All survey responses were summarized with descriptive statistics. Single-sample t tests were used to analyze responses to questions about whether statements are more indicative of UC or CD. The frequency at which each type of treatment was used as induction and maintenance therapies was analyzed using a mixed model, and a similar mixed model was used to assess differences in attribute agreement across treatments. A final mixed model was used to analyze differences with respect to the necessary duration of treatment before success (or lack thereof) could be established. All tests of significance were two-tailed.
RESULTS

Participant Characteristics
Participants (N = 500) in the phase 2 survey were predominantly male gastroenterologists between the ages of 35 and 64 years ( Table 1) . More than half of respondents were part of a private group practice, and the average time in practice was 16.5 years. Participants reported spending the vast majority of their time on direct patient care, seeing [300 patients per month on average.
Perceptions of UC vs. CD
Compared with CD, UC was perceived as easier to diagnose and having better treatment outcomes (Fig. 1a) . Survey respondents prescribed biologics earlier for CD than for UC. CD was perceived as having a greater effect than UC on patients' ability to perform daily activities (Fig. 1b) .
Determining UC Severity
Factors that physicians most commonly used to distinguish between mild and moderate UC included number of stools per day above normal, ulcerations on endoscopy, and rectal bleeding, each cited by [50% of respondents (Table 2) . Less commonly cited factors (cited by \50% but [20% of respondents) were anemia, impact on QoL, weight loss, hospitalizations per year, abdominal pain, nocturnal bowel movements, friability on endoscopy, and fever.
The top factors used to distinguish mild from moderate UC were also examined on the basis of various practitioner characteristics. No significant differences based on gender, practice setting (private vs. public/other), or practice type (group vs. solo) were noted.
However, gastroenterologists aged B44 years cited ulcerations on endoscopy as a top factor significantly more often than did those aged C45 years (data not shown).
Defining Clinical Remission in UC
Improved QoL was among the most often cited defining features of clinical remission, along with normalization of bowel habits, absence of rectal bleeding, return to normal daily activities, and complete mucosal healing (Fig. 2) .
UC Treatment Goals and Medication Performance Ratings
Treatment goals that were commonly considered most important by the survey participants included QoL improvement (31.2% of respondents), maintenance of clinical remission (17.4%), and mucosal healing (17.4%). When respondents rated the performance of each medication class in achieving each of these treatment goals, biologics had significantly higher ratings than all other classes (P\0.05), whereas 5-ASA agents commonly had the lowest ratings (Fig. 3) .
Medication Use by UC Severity
Medication class use by severity of UC was generally consistent with the traditional step-up approach to UC therapy [11] [12] [13] (Tables S2  and S3 in the supplementary material).
Duration of Treatment by Medication Class
Corticosteroids required the shortest duration of use before treatment success (or lack thereof) was determined; immunomodulators required the longest duration (Fig. 4) impacts of the disease as well as the disruptive effects of symptoms on day-to-day life while simultaneously overestimating disease control [18] . In addition, findings from a recent French survey study suggest that treatment with anti-tumor necrosis factor agents was significantly less common in patients with UC than in those with CD and that despite recent increases in available biologic treatment options, disease activity persists in many patients [19] .
The perceptions about UC highlighted herein may ultimately lead to suboptimal management approaches. In the current survey, UC steroid refractoriness and steroid dependency were the most commonly cited drivers for the initiation of biologic therapy, which implies that biologics are used relatively late in the disease course, consistent with the traditional step-up approach to therapy. Meanwhile, the recent literature suggests that treatment goals and therapeutic approaches for UC are evolving [11, 13, [20] [21] [22] [23] . The premise behind earlier use of more potent therapies is the potential for rapid induction of steroid-free remission and promotion of mucosal healing, which may modify the natural history of UC [23] .
As an alternative approach, some authors have suggested that structured treatment algorithms with specific time limits for evaluation of therapeutic success would be useful in guiding therapeutic decisions and achieving treatment goals [23] . The recently published Ulcerative Colitis Care Pathway b Fig. 1 [24] .
Treat-to-target strategies have also emerged, wherein treatment algorithms are geared toward a specific, well-defined target or targets, such as mucosal healing, histologic healing, or deep remission [11, 13, 21, 25] . In cases where a link between the pharmacokinetic and pharmacodynamic effects of a biologic agent has been well established, therapeutic drug monitoring with dosage adjustment to achieve a serum trough drug concentration target helps to improve outcomes and reduce costs [13, 21, 25] . Furthermore, assessment for the presence of anti-drug antibodies along with drug concentration monitoring could help guide treatment decisions [13, 26] . Several limitations of this study should be noted. First, as in any survey study and particularly in the context of honoraria provided for survey completion, the physician-reported data described herein may have been affected by recall bias, and there was no independent confirmation of data (e.g., frequency of medication use) from medical records. Survey participants may also have had characteristics that differ from those who chose not to participate; thus, results may not be generalizable to the overall gastroenterology population. In addition, the survey did not include questions about certain practice dynamics (e.g., typical frequency and duration of appointments, involvement of nurse practitioners or physician assistants in patients' care), which could have yielded useful insight on perceptions of UC. Finally, the survey did not allow participants to specify whether medications were used as monotherapy or as part of polytherapy, thus hindering the interpretation of medication use and duration of use data.
Despite these limitations, this study had numerous strengths, including its 2-phase design, wherein results from a small preliminary phone survey were used to inform the development of the large-scale, web-based Error bars represent 95% confidence intervals. ASA aminosalicylic acid and UC ulcerative colitis
